San Diego-centered Viking Therapeutics marked alone as a serious competitor within the weight loss drug sector in February soon after revealing promising information from the mid-phase trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when offered for a weekly injection As well as in March the com